January 11, 2015

BIVI FLEXcombo® swine vaccine now available in a 50-dose presentation

New smaller presentation size PCV2/M. hyo vaccine adds convenience, choice

Boehringer Ingelheim Vetmedica, Inc. (BIVI) makes it easier for producers and veterinarians to vaccinate pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae with a single injection of FLEXcombo®.

     FLEXcombo®, a member of the FLEX Family™ of vaccines, is now available in a 50-dose presentation, in addition to a 250-dose presentation, giving producers and veterinarians a choice of sizes that best fit their operations and number of pigs to vaccinate, with less wasted vaccine.

    According to Sarah Jorgensen, FLEX brand manager for the BIVI Swine Division, the packaging and mixing process for the 50-dose FLEXcombo® is the same as what producers are used to with the larger presentation size. “The 50-dose FLEXcombo® package contains a 50-mL bottle of Ingelvac CircoFLEX® and 50 mL of Ingelvac MycoFLEX® in a 100-mL headspace bottle for easy mixing. The result is 100 mL of mixed vaccine, enough to treat 50 head with a single 2-mL injection,” she explains.

    Producers and veterinarians have asked for a smaller presentation of FLEXcombo® so that they can better match vaccine quantity with the number of pigs they need to vaccine, while reducing the amount of left over vaccine.

    “Customers now have more choice in product size to go along with the added convenience of vaccinating pigs against two of the most important respiratory diseases in swine, all with a single injection,” Jorgensen adds. “More importantly, customers using either presentation size of FLEXcombo® can reduce stress on both pigs and people while decreasing labor costs because of the need for fewer injections. This all results in greater compliance with the Pork Quality Assurance Plus® program and improved pork quality.”

    For more information about FLEXcombo® and other FLEX Family™ swine vaccines, contact your veterinarian, visit www.bi-vetmedica.com or call BIVI at 800-325-9167.

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets. BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.